Nearly 2M Americans will develop cirrhosis from fatty liver disease – and there’s still no treatment. Joel Lewis joined “The Tape” show with @ptsweeney and @mg_miller to discuss drug aimed at helping patients survive without a liver transplant. https://t.co/pFuu4648i6

UPDATE: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023

We are excited to announce we will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases @AASLDtweets next week. Read more:  https://t.co/mHV9tmEKvc

Nearly 2M Americans will develop cirrhosis from fatty liver disease – and there’s still no treatment. Joel Lewis joined “The Tape” show with @ptsweeney and @mg_miller to discuss drug aimed at helping patients survive without a liver transplant.

Galectin will share five scientific presentations at The Liver Meeting 2022, hosted by @AASLDtweets this weekend. Get a preview of the abstracts at the link below. We look forward to seeing everyone attending AASLD.

A live webcast of the discussion will be available at the link below:

On 10/17/22, Galectin will present in the H.C. Wainwright 6th Annual NASH Investor Conference. Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation at the conference.

“This second IND is a significant milestone and exemplifies the dedication of our team towards furthering development of belapectin to better the lives of patients in a variety of important diseases." — Joel Lewis, President and CEO of Galectin Therapeutics

NEW: Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer https://t.co/4FoJJTYXBk

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 https://t.co/kZcR0miboV

Currently, there is no treatment for fatty liver disease other than diet & exercise, which are only somewhat effective in early stages of the disease. Which is why our clinical trial to develop a treatment for the late stages of this disease is so crucial. https://t.co/5P0RHcQ1Sh

With a staggering 80 to 100 million Americans affected, our clinical study exploring a new treatment for the late stages of the disease that can lead to liver failure is an important step forward.

With increasing frequency, doctors have seen ultrasound results demonstrating “fatty liver” in patients.

Interested in participating in the trial? Click here to see if you qualify and to learn more

👩‍⚕️ After an additional 18-months of treatment, doctors will perform another endoscopy 📊 Finally, the results of both phases of the trial will be analyzed to determine if belapectin should become an approved therapy for NASH cirrhosis

📊 After all patients receive at least 18 months of therapy, the results will be analyzed to determine which dosage of belapectin, if any, is most effective ✔️ Next, phase 3 stage will test the newly selected optimal dosage against a placebo

👀 The study is double-blind, so neither doctors nor patients will know who is receiving the medication or the placebo 👩‍⚕️ Doctors will perform an endoscopy at the beginning of the study and after 18 months of therapy to determine if the patient forms esophageal varices

🏥 The medication will be administered intravenously (IV) every other week at the trial site 🔎 The phase 2b stage will compare two dosages of belapectin against a placebo

Curious to know the process of GALT’s Phase 2b/3 NAVIGATE Study? Here’s a thread with what you need to know 👇

NASH #cirrhosis will soon become the number one reason for #liver transplants. $GALT is conducting research to change that in its NAVIGATE Study, the only adaptive Phase 2b/3 clinical trial focused on #NASH cirrhosis. Learn more here: